Is BeyondSpring Inc. (BYSI) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 1.0% / 30% | 4.9% / 30% | 0.0% / 30% | N/A | ✓ HALAL |
| DJIM | 1.0% / 33% | 4.9% / 33% | 0.0% / 33% | N/A | ✓ HALAL |
| MSCI | 1.7% / 33% | 8.5% / 33% | 0.0% / 33% | N/A | ✓ HALAL |
| S&P | 1.0% / 33% | 4.9% / 33% | 0.0% / 33% | N/A | ✓ HALAL |
| FTSE | 1.7% / 33% | 8.5% / 33% | 0.0% / 50% | N/A | ✓ HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Assets (ROA) | -18.6% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$16M |
| Free Cash Flow | -$17M |
| Total Debt | $589,000 |
| Current Ratio | 1.5 |
| Total Assets | $34M |
Price & Trading
| Last Close | $1.61 |
| 50-Day MA | $1.53 |
| 200-Day MA | $1.88 |
| Avg Volume | 35K |
|
52-Week Range
$0.98
| |
About BeyondSpring Inc. (BYSI)
BeyondSpring Inc., a clinical stage biopharmaceutical company, focuses on the development of cancer therapies. It operates through two segments: Plinabulin pipeline and TPD platform. The company's lead asset is the Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia. It is also developing Plinabulin in combination with docetaxel vs. docetaxel alone for the treatment of NSCLC and epidermal growth factor receptor wild type. In addition, the company develops Plinabulin in combination with various immuno-oncology agents and chemotherapy and radiation; nivolumab, a PD-1 antibody that is has completed phase 1 clinical trials for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer; in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers; and pembrolizumab, etoposide, and platinum to treat extensive-stage small cell lung cancer. Further, it engages in the development of three small molecule immune agents in preclinical stages; and a drug discovery platform to develop therapeutic agents from internal research and development efforts and from collaboration. The company was founded in 2010 and is headquartered in Florham Park, New Jersey.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is BeyondSpring Inc. (BYSI) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), BeyondSpring Inc. is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is BeyondSpring Inc.'s debt ratio?
BeyondSpring Inc.'s debt ratio is 1.0% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 1.7%.
What are BeyondSpring Inc.'s key financial metrics?
BeyondSpring Inc. has a market capitalization of $66M.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.